美国2型糖尿病患者非酒精性脂肪性肝病筛查具有成本效益：一项全面的成本效用分析。 - Suppr

Screening for Nonalcoholic Fatty Liver Disease in Persons with Type 2 Diabetes in the United States Is Cost-effective: A Comprehensive Cost-Utility Analysis.

作者信息

Noureddin Mazen, Jones Calum, Alkhouri Naim, Gomez Eduardo Vilar, Dieterich Douglas T, Rinella Mary E

机构信息

Division of Digestive and Liver Diseases, Comprehensive Transplant Center, Cedars Sinai Medical Center, Los Angeles, California.

Health Economics, McCann Health, Glasgow, United Kingdom.

出版信息

Gastroenterology. 2020 Nov;159(5):1985-1987.e4. doi: 10.1053/j.gastro.2020.07.050. Epub 2020 Aug 5.

DOI:10.1053/j.gastro.2020.07.050

PMID:32763241

Abstract

摘要

相似文献

Screening for Nonalcoholic Fatty Liver Disease in Persons with Type 2 Diabetes in the United States Is Cost-effective: A Comprehensive Cost-Utility Analysis.美国2型糖尿病患者非酒精性脂肪性肝病筛查具有成本效益：一项全面的成本效用分析。

Gastroenterology. 2020 Nov;159(5):1985-1987.e4. doi: 10.1053/j.gastro.2020.07.050. Epub 2020 Aug 5.

Cost-utility analysis of nonalcoholic steatohepatitis screening.非酒精性脂肪性肝炎筛查的成本效用分析

Eur Radiol. 2015 Nov;25(11):3282-94. doi: 10.1007/s00330-015-3731-2. Epub 2015 May 21.

Economic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the U.S.美国 2 型糖尿病患者非酒精性脂肪性肝炎的经济和临床负担

Diabetes Care. 2020 Feb;43(2):283-289. doi: 10.2337/dc19-1113. Epub 2019 Oct 28.

Nonalcoholic steatohepatitis (NASH) - current treatment recommendations and future developments.非酒精性脂肪性肝炎（NASH）——当前的治疗建议及未来发展

Z Gastroenterol. 2019 Apr;57(4):508-517. doi: 10.1055/a-0784-8827. Epub 2019 Apr 9.

Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD.成人糖尿病和非酒精性脂肪性肝病患者非酒精性脂肪性肝炎和晚期肝纤维化的临床模型：非酒精性脂肪性肝病转诊指南

Diabetes Care. 2015 Jul;38(7):1347-55. doi: 10.2337/dc14-1239. Epub 2015 Apr 17.

How to Approach a Patient With Nonalcoholic Fatty Liver Disease.如何诊治非酒精性脂肪性肝病患者。

Gastroenterology. 2017 Aug;153(2):345-349. doi: 10.1053/j.gastro.2017.06.016. Epub 2017 Jun 21.

Healthcare resource utilization and costs of nonalcoholic steatohepatitis patients with advanced liver disease in Italy.意大利晚期肝病非酒精性脂肪性肝炎患者的医疗资源利用和费用。

Nutr Metab Cardiovasc Dis. 2020 Jun 9;30(6):1014-1022. doi: 10.1016/j.numecd.2020.02.016. Epub 2020 Mar 5.

Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update.非酒精性脂肪性肝病组织学谱中的心血管风险及临床表现：最新进展

World J Gastroenterol. 2015 Jun 14;21(22):6820-34. doi: 10.3748/wjg.v21.i22.6820.

Cost-effectiveness analysis of ultrasonography screening for nonalcoholic fatty liver disease in metabolic syndrome patients.代谢综合征患者非酒精性脂肪性肝病超声筛查的成本效益分析

Medicine (Baltimore). 2017 Apr;96(17):e6585. doi: 10.1097/MD.0000000000006585.

Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.非酒精性脂肪性肝病治疗在 2 型糖尿病患者中；新的问题出现了。

Curr Vasc Pharmacol. 2020;18(2):172-181. doi: 10.2174/1570161117666190405164313.

引用本文的文献

Development of a novel deep learning method that transforms tabular input variables into images for the prediction of SLD.开发一种新型深度学习方法，该方法将表格输入变量转换为图像以预测睡眠呼吸障碍。

Sci Rep. 2025 Jul 31;15(1):28024. doi: 10.1038/s41598-025-12900-z.

Machine learning-based identification of biochemical markers to predict hepatic steatosis in patients at high metabolic risk.基于机器学习识别生化标志物以预测高代谢风险患者的肝脂肪变性

World J Gastroenterol. 2025 Jul 21;31(27):108200. doi: 10.3748/wjg.v31.i27.108200.

Assessment of metabolic dysfunction-associated fatty liver disease in primary care: a consensus statement summary.基层医疗中代谢功能障碍相关脂肪性肝病的评估：共识声明摘要

Med J Aust. 2025 Sep 1;223(5):268-276. doi: 10.5694/mja2.70008. Epub 2025 Jul 28.

A call for doubling the diagnostic rate of at-risk metabolic dysfunction-associated steatohepatitis.呼吁将有风险的代谢功能障碍相关脂肪性肝炎的诊断率提高一倍。

Lancet Reg Health Eur. 2025 Jun 4;54:101320. doi: 10.1016/j.lanepe.2025.101320. eCollection 2025 Jul.

Cost-effectiveness of advanced hepatic fibrosis screening in individuals with suspected MASLD identified by serologic noninvasive tests.通过血清学非侵入性检测识别的疑似代谢相关脂肪性肝病（MASLD）个体中晚期肝纤维化筛查的成本效益

Sci Rep. 2025 Jul 7;15(1):24186. doi: 10.1038/s41598-025-08434-z.

The Use of Non-i nvasive Biomarkers to Screen for Advanced Fibrosis Associated with Metabolic Dysfunction-associated Steatotic Liver Disease in People with Type 2 Diabetes: A Narrative Review.使用非侵入性生物标志物筛查2型糖尿病患者中与代谢功能障碍相关脂肪性肝病相关的晚期纤维化：一项叙述性综述

touchREV Endocrinol. 2025 May;21(1):24-31. doi: 10.17925/EE.2025.21.1.4. Epub 2025 Feb 20.

Cost-effectiveness analysis of MASLD screening using FIB-4 based two-step algorithm in the medical check-up.在体检中使用基于FIB-4的两步算法对代谢相关脂肪性肝病（MASLD）进行筛查的成本效益分析。

Sci Rep. 2025 Jun 2;15(1):19336. doi: 10.1038/s41598-025-01740-6.

Key Points and Future Directions from the 2024 Chinese Guidelines for Fatty Liver Disease.《2024年中国脂肪性肝病防治指南》要点与未来方向

J Clin Transl Hepatol. 2025 May 28;13(5):434-439. doi: 10.14218/JCTH.2025.00051. Epub 2025 Mar 27.

Non-Invasive Tests as a Replacement for Liver Biopsy in the Assessment of MASLD.非侵入性检测在评估代谢相关脂肪性肝病（MASLD）中替代肝活检的应用

Medicina (Kaunas). 2025 Apr 16;61(4):736. doi: 10.3390/medicina61040736.

Agile 3+ and 4 Scores Accurately Predict Major Adverse Liver Outcomes, Liver Transplant, Progression of MELD Score, the Development of Hepatocellular Carcinoma, and Death in NAFLD.Agile 3+和4评分能准确预测非酒精性脂肪性肝病（NAFLD）的主要不良肝脏结局、肝移植、终末期肝病模型（MELD）评分进展、肝细胞癌发生及死亡情况。

Dig Dis Sci. 2025 Mar 24. doi: 10.1007/s10620-025-08850-1.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Screening for Nonalcoholic Fatty Liver Disease in Persons with Type 2 Diabetes in the United States Is Cost-effective: A Comprehensive Cost-Utility Analysis.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

引用本文的文献